Clinilabs Selected for a Phase I/II Study of HIV Vaccine

Clinilabs announced that they have been selected to conduct a Phase I/II clinical research study of an investigational vaccine for HIV.
 
According to Dr. Howard Greenberg, Senior Medical Director of Clinilabs, "Conducting early phase clinical trials with a novel therapeutic in a new patient population is a major advance in Clinilabs’ progression as a CRU.”

Greenberg also notes that conducting vaccine studies and expanding enrollment of specialty patient populations are two key strategic directions Clinilabs is pursuing to capitalize on its position as a global CRO that operates a CRU in New York City, a hub of academic medical centers and home to a diverse population of more than 19 million potential research subjects.

Enrollment for this study is expected to begin later this month.